News | Radiopharmaceuticals and Tracers | May 13, 2016

Blue Earth Diagnostics Opens U.S. Office, Expands Management Team

Massachusetts office will provide support for development and commercialization of PET imaging agent pending FDA approval

Blue Earth Diagnostics, U.S. headquarters, management expansion, PET imaging agent

May 13, 2016 — Blue Earth Diagnostics, a molecular imaging diagnostics company, announced it has established operations in the United States in Burlington, Mass. The company develops and commercializes innovative positron emission tomography (PET) imaging products that address unmet needs in cancer.

The Massachusetts headquarters will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F-18, the company’s PET imaging agent currently under Priority Review with the U.S. Food and Drug Administration (FDA).

The company also announced the creation of key appointments for Blue Earth Diagnostics Inc.:  Michael W. Heslop, as president; Peter Gardiner, MB ChB, MRCP, FFPM, as vice president, medical affairs; Bradley K. Pounds as vice president, sales, U.S.; David Pendleton, vice president, marketing; Christa Dhimo, vice president, strategy & execution, U.S.; and Priscilla Harlan, vice president, corporate communications.

Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.

For more information: www.blueearthdiagnostics.com

Related Content

Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...